Physician profile
John Baker
NPI 1598922130
$779,476.34
in general payments reported to CMS, 2019-2025
76 companies · $162K in 2025
The $162K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111K · 2020: $81K · 2021: $88K · 2022: $112K · 2023: $97K · 2024: $129K · 2025: $162K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $272K · Consulting Fee: $44K · Food and Beverage: $25K · Travel and Lodging: $23K · Honoraria: $23K · Education: $1,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $272,400.00 |
| Consulting Fee | $43,843.39 |
| Food and Beverage | $25,065.85 |
| Travel and Lodging | $22,783.64 |
| Honoraria | $22,550.00 |
| Education | $1,337.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $102,907.44 | 2019-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $102,676.12 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $92,849.94 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Emd Serono, INC. | $77,961.09 | 2019-2025 | Mavenclad, Mavenclad |
| Amgen INC. | $54,439.10 | 2019-2025 | Uplizna |
| Genzyme Corporation | $39,296.34 | 2019-2025 | |
| Pfizer INC. | $34,881.12 | 2021-2025 | |
| Allergan, INC. | $28,734.69 | 2019-2022 | |
| Lundbeck LLC | $24,872.25 | 2020-2025 | Vyepti, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $23,107.93 | 2020-2025 | Zeposia |
| Eisai INC. | $20,922.30 | 2019-2024 | |
| Ucb, INC. | $18,826.42 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Otsuka America Pharmaceutical, INC. | $18,295.13 | 2023-2025 | Rexulti, Nuedexta |
| Biohaven Pharmaceutical Holding Company Ltd. | $16,543.49 | 2022 | |
| Ani Pharmaceuticals, INC. | $13,467.93 | 2022-2025 | Purified Cortrophin Gel |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $13,263.53 | 2020-2021 | |
| Tg Therapeutics, INC. | $12,899.00 | 2023-2025 | |
| Neurelis, INC. | $10,825.56 | 2020-2024 | Valtoco |
| Sk Life Science, INC. | $10,811.24 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $10,233.12 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $9,981.71 | 2019-2025 | |
| Aquestive Therapeutics, INC. | $5,965.07 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $5,075.75 | 2020-2025 | Ongentys, Ongentys 50mg Capsules 30, Crexont |
| Celgene Corporation | $4,942.72 | 2021-2025 | Zeposia |
| Acorda Therapeutics, INC | $4,146.16 | 2019-2024 | Inbrija |
| Lilly USA, LLC | $3,838.81 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Catalyst Pharmaceuticals, INC. | $2,766.17 | 2019-2025 | Fycompa |
| Livanova USA, INC. | $2,220.12 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Sunovion Pharmaceuticals INC. | $1,825.57 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $1,712.91 | 2019-2025 | Ultomiris, Soliris |
| Promius Pharma LLC | $1,269.41 | 2019 | |
| Biogen, INC. | $837.41 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Currax Pharmaceuticals LLC | $514.69 | 2020-2025 | Contrave, Onzetra Xsail |
| Csl Behring | $488.34 | 2019-2024 | Hizentra |
| Mallinckrodt Hospital Products INC. | $454.31 | 2020-2025 | Acthar |
| Jazz Pharmaceuticals INC. | $450.57 | 2019-2024 | |
| Dr.Reddy'S Laboratories,INC. | $400.00 | 2019 | |
| Genentech USA, INC. | $390.72 | 2019-2024 | Ocrevus, Enspryng |
| Octapharma USA, INC. | $341.86 | 2023-2025 | Panzyga |
| Mdd US Operations, LLC | $336.00 | 2020-2025 | Gocovri, Gocovri |
| Supernus Pharmaceuticals, INC. | $286.89 | 2019-2025 | Qelbree |
| Merz Pharmaceuticals, LLC | $277.17 | 2022-2024 | Xeomin |
| Upsher-Smith Laboratories LLC | $244.14 | 2019-2022 | |
| Axsome Therapeutics, INC. | $204.28 | 2024-2025 | Sunosi, Symbravo |
| Impel Pharmaceuticals INC. | $204.18 | 2022-2023 | Trudhesa |
| Avanir Pharmaceuticals, INC. | $190.44 | 2019-2021 | |
| Argenx US, INC. | $168.06 | 2022-2023 | Vyvgart |
| Astrazeneca Pharmaceuticals Lp | $165.40 | 2023-2025 | Wainua |
| Alnylam Pharmaceuticals INC. | $163.44 | 2021-2024 | Onpattro |
| Kyowa Kirin, INC. | $149.06 | 2019-2024 | Nourianz |
| Greenwich Biosciences, INC. | $127.72 | 2020 | |
| Tanabe Pharma America, INC. | $122.89 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $120.59 | 2023-2024 | Aptiom |
| Bausch Health US, LLC | $118.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.00 | 2023-2024 | Hyqvia |
| Grifols USA, LLC | $111.75 | 2019-2024 | Gamunex-C |
| Harmony Biosciences LLC | $105.81 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $100.16 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $96.98 | 2021-2024 | Ponvory |
| Mallinckrodt Enterprises LLC | $84.22 | 2019 | |
| Adamas Pharmaceuticals, INC. | $72.63 | 2019-2020 | |
| Amylyx Pharmaceuticals, INC. | $55.90 | 2023 | Relyvrio |
| Acadia Pharmaceuticals INC | $53.63 | 2019-2024 | Nuplazid |
| Banner Life Sciences, LLC | $53.61 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $52.16 | 2023-2024 | Horizant, Horizant |
| Assertio Therapeutics, INC. | $50.31 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $39.95 | 2024 | Dysport |
| Cala Health, INC. | $29.31 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.84 | 2023 | |
| Scilex Pharmaceuticals INC. | $22.94 | 2024 | |
| Insightec,INC | $21.96 | 2024 | Exablate |
| Avion Pharmaceuticals | $18.73 | 2022 | |
| Mylan Pharmaceuticals INC. | $14.75 | 2019 | |
| Horizon Therapeutics Plc | $14.56 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.60 | 2023 | Quviviq |
| Zyla Life Sciences, INC. | $11.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.